Proactive Investors - Run By Investors For Investors

Compound selection for brain cancer therapy 'a significant milestone' for Midatech

Jim Phillips, chief executive of Midatech Pharma Plc (LON:MTPH NASDAQ:MTP) tells Proactive they've selected their preferred compound candidate for testing as a potential therapy for glioblastoma (GBM), a rare form of brain cancer.

 
Meet Metro Mining Ltd and Elementos Ltd at our event, Melbourne , 10 April 2019. Register here »
View full MTPH profile View Profile

Midatech Pharma PLC Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use